In an Interview with Stock-Sector, Duke Explains How Pulmatrix’s Innovative Technology is Targeting Major Unmet Medical Needs and has Potential to Bring the Company a Share of a $33 Billion Market
NEW YORK, NY / ACCESSWIRE / May 17, 2017 / Stock-Sector.com, an online source of news about promising medical, technology and energy companies, and CEOCFO Magazine, an independent investment publication that highlights important technologies and companies, today released an interview with William Duke, Jr., CFO of Pulmatrix, Inc., (PULM).
Pulmatrix, a clinical stage biopharmaceutical company, is developing an inhaled therapy for treating fungal infections in patients suffering from severe lung disease (PUR1900) that has “blockbuster” potential, Bill Duke told Stock-Sector.
“The global market for inhaled products is expected to grow to be $33 billion by 2019,” Duke explained. “So we believe that there is a significant opportunity to both serve patients and build a profitable company.”
Pulmatrix’s key innovation was the development of a new technology for delivering drugs to the lungs, called iSPERSETM. Other inhaled technologies have limitations, said Duke. “They leave too much drug behind in the device or stuck in the throat.” That reduces efficacy and causes side effects.
Pulmatrix has solved these problems by creating tiny particles that look like raisins, with nooks and crannies. Because the particles are dense and don’t stick together, “They fly easily in the lungs and can deliver virtually any type of drug,” said Duke. Far more of the drug makes it to the lungs, where it is needed to treat disease, and far less sticks in the throat, causing the side effects.
Duke told Stock-Sector that Pulmatrix currently is developing an inhaled bronchodilator for chronic obstructive pulmonary disease, PUR0200, and an inhaled anti-fungal drug, PUR1900, for treating fungal infections in the lungs of patents with cystic fibrosis and severe asthma. Pilot studies show both product candidates deliver drugs to the lungs with very high efficiency. PUR1900 has also been granted orphan drug status and Qualified Infectious Disease Product (QIDP) status by the Food & Drug Administration and expects to pursue the 505(b)(2) regulatory pathway for regulatory approval, which may speed the path to market.
In addition, said Duke, “There are many opportunities for other drugs that can benefit from our iSPERSE technology.”
All of this means a bright future for the company. “We are extremely excited about Pulmatrix’s potential,” said Duke.
Stock-Sector is an online source of news about promising medical, technology, and energy companies. Stock-Sector was created out of necessity, to provide a glimpse of the financial markets in sectors relevant to the investor. We strive to deliver easily digestible content to the overburdened stockholder. Another significant focus of ours is to establish compelling media to heighten the experience in neglected humdrum industries.
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may,” “will,” “should,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” and similar expressions identify forward-looking statements.
Actual results, performance, or events may differ materially from those in such statements due to, without limitation, (i) general economic conditions, (ii) performance of financial markets, including emerging markets, and including market volatility, liquidity and credit events (iii) the frequency and severity of insured loss events, including from natural catastrophes and including the development of loss expenses, (iv) mortality and morbidity levels and trends, (v) persistency levels, (vi) the extent of credit defaults, (vii) interest rate levels, (viii) currency exchange rates including the Euro/U.S. Dollar exchange rate, (ix) changing levels of competition, (x) changes in laws and regulations, (xi) changes in the policies of central banks and/or foreign governments, (xii) the impact of acquisitions, including related integration issues, (xiii) reorganization measures, and (xiv) general competitive factors, in each case on a local, regional, national and/or global basis.